IP Library › Granted Patent US 7,582,624
Granted Patent B2
US 7,582,624 · App. 10/528,250 · Granted Sep 1, 2009

Benzodiazepine derivatives and pharmaceutical compositions containing them

Assignee: Arrow Therapeutics Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,582,624
App. No.
10/528,250
Granted
Sep 1, 2009
Kind
B2
Abstract

Benzodiazepine derivative of formula (I), and pharmaceutically acceptable salts thereof, are found to be active against RSV. Formula (I) Wherein: —R 1 represents C 1-6 alkyl, aryl or heteroaryl; —R 2 represents hydrogen or C 1-6 alkyl; —each R 3 is the same or different and represents halogen, hydroxy, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkylthio, C 1-6 haloalkyl, C 1-6 haloalkoxy, amino, mono(C 1-6 alkyl)amino, di(C 1-6 alkyl)amino, nitro, cyano, —CO 2 R′, —CONR′R″, —NH—CO—R′, —S(O)R′, —S(O) 2 R′, —NH—S(O) 2 R′, —S(O)NR′R″ or —S(O) 2 NR′R″ wherein each R′ and R″ is the same or different and represents hydrogen or C 1-6 alkyl; —n is from 0 to 3; R 4 represents hydrogen or C 1-6 alkyl; —R 6 represents C 1-6 alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C 1-6 alkyl)-, heteroaryl-(C 1-6 alkyl)-, carbocyclyl-(C 1-6 alkyl)-, heterocyclyl-(C 1-6 alkyl)-, aryl-C(O)—C(O)—, heteroaryl-C(O)—C(O)—, carbocyclyl-C(O)—C(O)—, heterocyclyl-C(O)—C(O)— or, —XR 6 ; —X represents —CO—, —S(O)— or —S(O) 2 —; and —R 6 represents C 1-6 alkyl, hydroxy, C 1-6 alkoxy, C 1-6 alkylthio, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C 1-6 alkyl)-, heteroaryl-(C 1-6 alkyl)-, carbocyclyl-(C 1-6 alkyl)-, heterocyclyl-(C 1-6 alkyl)-, aryl-(C 1-6 hydroxyalkyl)-, heteroaryl-(C 1-6 hydroxyalkyl)-, carbocyclyl-(C 1-6 hydroxyalkyl)-, heterocyclyl-(C 1-6 hydroxyalkyl)-, aryl-(C 1-6 alkyl)-O—, heteroaryl-(C 1-6 alkyl)-O—, carbocyclyl-(C 1-6 alkyl)-O—, heterocyclyl-(C 1-6 alkyl)-O— or —NR′R″ wherein each R′ and R″ is the same or different and represents hydrogen, C 1-6 alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, aryl-(C 1-6 alkyl)-, heteroaryl-(C 1-6 alkyl)-, carbocyclyl-(C 1-6 alkyl)- or heterocyclyl-(C 1-6 alkyl)-.

Claims (29)

1. A compound of formula (Ic), or a pharmaceutically acceptable salt thereof,

wherein:

R 1 is phenyl;

R 3 is methyl or chlorine;

n is 0 or 1;

R 4 is hydrogen or methyl;

R 5 ′ is —X′;

X′ is —CONR′R″ and

each R′ R″ is the same or different and represents hydrogen, C 1-4 alkyl, phenyl, thienyl, cyclohexyl, cyclopentyl or phenyl-(CH 2 )—;

wherein:

the phenyl moiety in the group R 1 being unsubstituted or substituted by a single C 1-2 alkyl, C 1-2 alkoxy, C 1-2 alkylthio, C 1-2 haloalkyl or C 1-2 haloalkoxy substituent;

the phenyl, thienyl, cyclohexyl, cyclopentyl or phenyl-(CH 2 )— moieties in the R′ and R″ being unsubstituted or substituted by one or two substituents selected from fluorine, chlorine, bromine, and nitro.

2. A compound of formula (Ie) or pharmaceutically acceptable salts thereof

wherein R′* is an aryl group which is unsubstituted or substituted by 1 or 2 substituents selected from fluorine, chlorine, bromine, and nitro.

3. A compound according to claim 1 , selected from 1,1-Diethyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;

(S)-1-(2-Fluoro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;

1-(4-Nitro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;

1-tert-Butyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;

1-Cyclohexyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;

1-Ethyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;

1-Butyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea;

or a pharmaceutically acceptable salt thereof.

4. The compound of claim 2 , wherein R′* is a phenyl group which is unsubstituted or substituted by a single fluorine, chlorine, or bromine substituent.

5. A compound according to claim 2 , wherein the compound is (S)-1 -(2-Fluoro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea.

6. A compound according to claim 2 , wherein the compound is 1-(4-Nitro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea.

7. A compound according to claim 2 , wherein the compound is 1-Butyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea.

8. A compound according to claim 1 wherein the compound is 1,1-Diethyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea.

9. A compound according to claim 2 , wherein the compound is 1-tert-Butyl-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-urea.

10. A compound according to claim 1 , wherein R 1 is phenyl.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 27, 2007
From: DOWDELL, VERITY
To: ARROW THERAPEUTICS LIMITED
Reel/Frame 019226/0668 →
SECURITY AGREEMENT Recorded Jun 22, 2006
From: ARROW THERAPEUTICS LIMITED
To: GE LEVERAGED LOANS LIMITED
Reel/Frame 017830/0987 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 21, 2005
From: CARTER, MALCOLM; HENDERSON, ELISA; KELSEY, RICHARD; WILSON, LARA; CHAMBERS, PHIL; TAYLOR, DEBRA; TYMS, STAN
To: ARROW THERAPEUTICS LIMITED
Reel/Frame 016375/0849 →
Priority Claims (2)
GB 0221923.6 · Sep 20, 2002 · national
GB 0302078.1 · Jan 29, 2003 · national
Continuity (1)
Related Publication 20060040923A1 · Feb 23, 2006